Ultragenyx Pharmaceutical Inc. announced that, as of September 8, 2025, its DTX401 gene therapy showed significant reductions in cornstarch intake for patients with GSDIa, achieving a 61% reduction by Week 96, with impressive improvements in glycemic control and quality of life reported. This Phase 3 study involved 20 treated patients and indicated strong potential for regulatory approval.